Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Study summary

This phase I trial is evaluating a new imaging tracer (68Ga-FAPi-46) with positron emission tomography (PET)/computed tomography (CT) to determine where and to which degree the tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues (the biodistribution) in patients with solid tumors or hematologic (blood) cancers. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 68Ga-FAPi-46. Because some cancers take up 68Ga-FAPi-46, it can be seen with PET. CT utilizes x-rays that traverse the body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in a patient's body. Combining a PET scan with a CT scan can help make the image easier to interpret. PET/CT scans are hybrid scanners that combine both modalities into a single scan during the same examination.

Ask AI to explain this study

Start here

Key things to know

Main goalDiagnostic

This describes the study’s primary purpose.

What is being studiedComputed Tomography and Fludeoxyglucose F-18

Plus 2 other study approaches.

Who it may be forAnal Carcinoma · Bladder Carcinoma

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 20, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Phase 1

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Jonsson Comprehensive Cancer Center

Study sponsor

Study overview

What this study is about

Purpose: Diagnostic
Study type: Interventional
Phase: Phase 1
Sponsor: Jonsson Comprehensive Cancer Center
Interventions being studied: Procedure: Computed Tomography; Other: Fludeoxyglucose F-18; Radiation: Gallium Ga 68 FAPi-46; Procedure: Positron Emission Tomography

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Patients with the following suspected or diagnosed cancer types:
Adrenal cancer
Anal cancer
Bladder cancer
Brain cancer
Breast cancer
Cancer of unknown primary (CUP)
Cervical cancer
Cholangiocarcinoma
Colorectal cancer
Esophageal cancer
Gastric cancer
Head and neck cancer
Hematologic cancer
Hepatocellular carcinoma
Lung cancer
Medullary thyroid cancer
Neuroendocrine neoplasias
Ovarian cancer
Pancreatic cancer
Penile cancer
Peritoneal cancer
Pleural cancer
Prostate cancer
Sarcoma
Salivary gland cancer
Solitary fibrous tumor
Skin cancer
Testicular cancer
Thymus cancer
Thyroid cancer
Urothelial cancer
Uterus cancer
Vaginal cancer
Patients are ≥ 18 years old at the time of the radiotracer administration
Patient can provide written informed consent
Patient is able to remain still for duration of imaging procedure (up to one hour)

Reasons someone may not be able to joinExclusion criteria

Patient is pregnant or nursing
Patient has underlying disease which, based on the judgment of the investigator, might interfere with the collection of high-quality data

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

UCLA / Jonsson Comprehensive Cancer CenterLos Angeles, California

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 20, 2026. Always confirm current availability with the study team.

View original record ↗